References
1. Grzeskowiak LE, Mol BW. Off-label prescribing in pregnancy-a case of
risky business or business as usual? Eur J Obstet Gynecol Reprod Biol
2015; 187: 78-9.
2. Adam MP, Polifka JE, Friedman JM. Evolving knowledge of the
teratogenicity of medications in human pregnancy. Am J Med Genet C Semin
Med Genet 2011; 157C: 175-82.
3. van der Graaf R, van der Zande ISE, den Ruijter HM, Oudijk MA, van
Delden JJM, Oude Rengerink K, Groenwold RHH. Fair inclusion of pregnant
women in clinical trials: an integrated scientific and ethical approach.
Trials 2018; 19: 78.
4. Somers GS. Thalidomide and congenital abnormalities. Lancet 1962; 1:
912-3.
5. Troisi R, Hatch EE, Titus L. The Diethylstilbestrol Legacy: A
Powerful Case Against Intervention in Uncomplicated Pregnancy.
Pediatrics 2016; 138: S42-S44.
6. Herbst AL, Scully RE. Adenocarcinoma of the vagina in adolescence. A
report of 7 cases including 6 clear-cell carcinomas (so-called
mesonephromas). Cancer 1970; 25: 745-57.
7. Sheffield JS, Siegel D, Mirochnick M, Heine RP, Nguyen C, Bergman KL,
Savic RM, Long J, Dooley KE, Nesin M. Designing drug trials:
considerations for pregnant women. Clin Infect Dis 2014; 59 Suppl 7:
S437-44.
8. Briggs GG, Freeman RK, Tower CV. Drugs in Pregnancy and Lactation: A
Reference Guide to Fetal and Neonatal Risk. 12 Editon. Baltimore:
Lippincott Williams & Wilkins (LWW), 2021.
9. Regulations UCoF. Protection of human subjects. 45 CFR 46, Subpart B.
In, 2009.
10. Ances BM. New concerns about thalidomide. Obstet Gynecol 2002; 99:
125-8.
11. Blehar MC, Spong C, Grady C, Goldkind SF, Sahin L, Clayton JA.
Enrolling pregnant women: issues in clinical research. Womens Health
Issues 2013; 23: e39-45.
12. Lyerly AD, Little MO, Faden R. The second wave: Toward responsible
inclusion of pregnant women in research. Int J Fem Approaches Bioeth
2008; 1: 5-22.
13. Kazma JM, van den Anker J, Allegaert K, Dallmann A, Ahmadzia HK.
Anatomical and physiological alterations of pregnancy. J Pharmacokinet
Pharmacodyn 2020; 47: 271-85.
14. Torres-Vergara P, Escudero C, Penny J. Drug Transport at the Brain
and Endothelial Dysfunction in Preeclampsia: Implications and
Perspectives. Front Physiol 2018; 9: 1502.
15. Lo WY, Friedman JM. Teratogenicity of recently introduced
medications in human pregnancy. Obstet Gynecol 2002; 100: 465-73.
16. Vargesson N. Thalidomide-induced teratogenesis: history and
mechanisms. Birth Defects Res C Embryo Today 2015; 105: 140-56.
17. Griffiths SK, Campbell JP. Placental structure, function and drug
transfer. Bja Educ 2015; 15: 84-89.
18. Mirkin BL. Perinatal pharmacology: placental transfer, fetal
localization, and neonatal disposition of drugs. Anesthesiology 1975;
43: 156-70.
19. Dimitrakakis C, Papageorgiou P, Papageorgiou I, Antzaklis A,
Sakarelou N, Michalas S. Absence of transplacental passage of the low
molecular weight heparin enoxaparin. Haemostasis 2000; 30: 243-48.
20. Desoye G, Hofmann HH, Weiss PAM. Insulin Binding to Trophoblast
Plasma-Membranes and Placental Glycogen-Content in Well-Controlled
Gestational Diabetic Women Treated with Diet or Insulin, in
Well-Controlled Overt Diabetic-Patients and in Healthy Control Subjects.
Diabetologia 1992; 35: 45-55.
21. Brownbill P, Sebire N, McGillick EV, Ellery S, Murthi P. Ex Vivo
Dual Perfusion of the Human Placenta: Disease Simulation, Therapeutic
Pharmacokinetics and Analysis of Off-Target Effects. Methods Mol Biol
2018; 1710: 173-89.
22. Devkota R, Khan GM, Alam K, Sapkota B, Devkota D. Impacts of
counseling on knowledge, attitude and practice of medication use during
pregnancy. BMC Pregnancy Childbirth 2017; 17: 131.
23. Kennedy DA, Lupattelli A, Koren G, Nordeng H. Herbal medicine use in
pregnancy: results of a multinational study. BMC Complement Altern Med
2013; 13: 355.
24. Cohen LS, Altshuler LL, Harlow BL, Nonacs R, Newport DJ, Viguera AC,
Suri R, Burt VK, Hendrick V, Reminick AM, Loughead A, Vitonis AF, Stowe
ZN. Relapse of major depression during pregnancy in women who maintain
or discontinue antidepressant treatment. JAMA 2006; 295: 499-507.
25. Koren G, Pastuszak A. Prevention of unnecessary pregnancy
terminations by counselling women on drug, chemical, and radiation
exposure during the first trimester. Teratology 1990; 41: 657-61.
26. Henderson E, Mackillop L. Prescribing in pregnancy and during breast
feeding: using principles in clinical practice. Postgrad Med J 2011; 87:
349-54.
27. Sun D, Hutson JR, Garcia-Bournissen F. Drug therapy during
pregnancy. Br J Clin Pharmacol 2020.
28. Tomasulo P. LactMed-new NLM database on drugs and lactation. Med Ref
Serv Q 2007; 26: 51-8.
29. Fitzpatrick RB. REPROTOX: an information system on environmental
hazards to human reproduction and development. Med Ref Serv Q 2008; 27:
73-80.
30. Hayes DK, Robbins CL, Ko JY. Trends in Selected Chronic Conditions
and Related Risk Factors Among Women of Reproductive Age: Behavioral
Risk Factor Surveillance System, 2011-2017. J Womens Health (Larchmt)
2020; 29: 1576-85.
31. National Heart L, Blood I, National Asthma E, Prevention Program A,
Pregnancy Working G. NAEPP expert panel report. Managing asthma during
pregnancy: recommendations for pharmacologic treatment-2004 update. J
Allergy Clin Immunol 2005; 115: 34-46.
32. Zetstra-van der Woude PA, Vroegop JS, Bos HJ, de Jong-van den Berg
LT. A population analysis of prescriptions for asthma medications during
pregnancy. J Allergy Clin Immunol 2013; 131: 711-7.
33. Murphy VE, Gibson PG. Asthma in pregnancy. Clin Chest Med 2011; 32:
93-110.
34. Fraser FC, Fainstat TD. Production of congenital defects in the
off-spring of pregnant mice treated with cortisone; progress report.
Pediatrics 1951; 8: 527-33.
35. Karalis DG, Hill AN, Clifton S, Wild RA. The risks of statin use in
pregnancy: A systematic review. J Clin Lipidol 2016; 10: 1081-90.
36. Adminstration FAD. FDA Drug Safety Communication. In, 2021.
37. Lateef A, Petri M. Managing lupus patients during pregnancy. Best
Pract Res Clin Rheumatol 2013; 27: 435-47.
38. Broms G, Granath F, Linder M, Stephansson O, Elmberg M, Kieler H.
Birth outcomes in women with inflammatory bowel disease: effects of
disease activity and drug exposure. Inflamm Bowel Dis 2014; 20: 1091-8.
39. Rom AL, Wu CS, Olsen J, Kjaergaard H, Jawaheer D, Hetland ML,
Vestergaard M, Morch LS. Fetal growth and preterm birth in children
exposed to maternal or paternal rheumatoid arthritis: a nationwide
cohort study. Arthritis Rheumatol 2014; 66: 3265-73.
40. Rubin R. Addressing Barriers to Inclusion of Pregnant Women in
Clinical Trials. JAMA 2018; 320: 742-44.
41. Kaposy C. Presumptive Inclusion and Legitimate Exclusion Criteria.
In: Clinical Research Involving Pregnant Women, edsBaylis F, Ballantyne
A, Cham: Springer, 2016.
42. Payne P. Including Pregnant Women in Clinical Research: Practical
Guidance for Institutional Review Boards. Ethics Hum Res 2019; 41:
35-40.
43. Administration. USFaD. Pregnant Women: Scientific and Ethical
Considerations for Inclusion in Clinical Trials Guidance for Industry -
Draft Guidance. In, 2018.
44. McCullough LB, Coverdale JH, Chervenak FA. A comprehensive ethical
framework for responsibly designing and conducting pharmacologic
research that involves pregnant women. Am J Obstet Gynecol 2005; 193:
901-7.
45. Taylor MM, Kobeissi L, Kim C, Amin A, Thorson AE, Bellare NB,
Brizuela V, Bonet M, Kara E, Thwin SS, Kuganantham H, Ali M, Oladapo OT,
Broutet N. Inclusion of pregnant women in COVID-19 treatment trials: a
review and global call to action. Lancet Glob Health 2021; 9: e366-e71.
46. Gonzalez D, Boggess KA, Cohen-Wolkowiez M. Lessons learned in
pediatric clinical research to evaluate safe and effective use of drugs
in pregnancy. Obstet Gynecol 2015; 125: 953-58.
47. Laughon MM, Benjamin DK, Jr., Capparelli EV, Kearns GL, Berezny K,
Paul IM, Wade K, Barrett J, Smith PB, Cohen-Wolkowiez M. Innovative
clinical trial design for pediatric therapeutics. Expert Rev Clin
Pharmacol 2011; 4: 643-52.
48. Benjamin DK, Jr., Smith PB, Murphy MD, Roberts R, Mathis L, Avant D,
Califf RM, Li JS. Peer-reviewed publication of clinical trials completed
for pediatric exclusivity. JAMA 2006; 296: 1266-73.
49. De Sousa Mendes M, Hirt D, Vinot C, Valade E, Lui G, Pressiat C,
Bouazza N, Foissac F, Blanche S, Le MP, Peytavin G, Treluyer JM, Urien
S, Benaboud S. Prediction of human fetal pharmacokinetics using ex vivo
human placenta perfusion studies and physiologically based models. Br J
Clin Pharmacol 2016; 81: 646-57.
50. Zhang Z, Unadkat JD. Development of a Novel Maternal-Fetal
Physiologically Based Pharmacokinetic Model II: Verification of the
model for passive placental permeability drugs. Drug Metab Dispos 2017;
45: 939-46.
51. Benaboud S, Treluyer JM, Urien S, Blanche S, Bouazza N, Chappuy H,
Rey E, Pannier E, Firtion G, Launay O, Hirt D. Pregnancy-related effects
on lamivudine pharmacokinetics in a population study with 228 women.
Antimicrob Agents Chemother 2012; 56: 776-82.
52. Alsaied T, Baskar S, Fares M, Alahdab F, Czosek RJ, Murad MH, Prokop
LJ, Divanovic AA. First-Line Antiarrhythmic Transplacental Treatment for
Fetal Tachyarrhythmia: A Systematic Review and Meta-Analysis. J Am Heart
Assoc 2017; 6.
53. Fung HB, Kirschenbaum HL. Treatment regimens for patients with
toxoplasmic encephalitis. Clin Ther 1996; 18: 1037-56; discussion 36.
54. Di Carlo R, Pagnini G, Pelagalli GV. Effect of amitriptyline and
butriptyline on fetal development in rats. J Med 1971; 2: 271-5.
55. Beyer BK, Guram MS, Geber WF. Incidence and potentiation of external
and internal fetal anomalies resulting from chlordiazepoxide and
amitriptyline alone and in combination. Teratology 1984; 30: 39-45.
56. Altshuler LL, Cohen L, Szuba MP, Burt VK, Gitlin M, Mintz J.
Pharmacologic management of psychiatric illness during pregnancy:
dilemmas and guidelines. Am J Psychiatry 1996; 153: 592-606.
57. Pastuszak A, Schick-Boschetto B, Zuber C, Feldkamp M, Pinelli M,
Sihn S, Donnenfeld A, McCormack M, Leen-Mitchell M, Woodland C, et al.
Pregnancy outcome following first-trimester exposure to fluoxetine
(Prozac). JAMA 1993; 269: 2246-8.
58. Munk-Olsen T, Liu XQ, Viktorin A, Brown HK, Di Florio A, D’Onofrio
BM, Gomes T, Howard LM, Khalifeh H, Krohn H, Larsson H, Lichtenstein P,
Taylor CL, Van Kamp I, Wesseloo R, Meltzer-Brody S, Vigod SN, Bergink V.
Maternal and infant outcomes associated with lithium use in pregnancy:
an international collaborative meta-analysis of six cohort studies.
Lancet Psychiat 2018; 5: 644-52.
59. Diav-Citrin O, Shechtman S, Tahover E, Finkel-Pekarsky V, Arnon J,
Kennedy D, Erebara A, Einarson A, Ornoy A. Pregnancy Outcome Following
In Utero Exposure to Lithium: A Prospective, Comparative, Observational
Study. Am J Psychiat 2014; 171: 785-94.
60. Baldwin JA, Davidson EJ, Pritchard AL, Ridings JE. The reproductive
toxicology of paroxetine. Acta Psychiatr Scand Suppl 1989; 350: 37-9.
61. Holzgreve W, Carey JC, Hall BD. Warfarin-induced fetal
abnormalities. Lancet 1976; 2: 914-5.
62. Donofrio MT, Moon-Grady AJ, Hornberger LK, Copel JA, Sklansky MS,
Abuhamad A, Cuneo BF, Huhta JC, Jonas RA, Krishnan A, Lacey S, Lee W,
Michelfelder EC, Sr., Rempel GR, Silverman NH, Spray TL, Strasburger JF,
Tworetzky W, Rychik J, American Heart Association Adults With Congenital
Heart Disease Joint Committee of the Council on Cardiovascular Disease
in the Y, Council on Clinical Cardiology CoCS, Anesthesia, Council on C,
Stroke N. Diagnosis and treatment of fetal cardiac disease: a scientific
statement from the American Heart Association. Circulation 2014; 129:
2183-242.
63. Reinisch JM, Simon NG, Karow WG, Gandelman R. Prenatal exposure to
prednisone in humans and animals retards intrauterine growth. Science
1978; 202: 436-8.
64. Bandoli G, Palmsten K, Smith CJF, Chambers CD. A Review of Systemic
Corticosteroid Use in Pregnancy and the Risk of Select Pregnancy and
Birth Outcomes. Rheum Dis Clin N Am 2017; 43: 489.
65. Harrod MJ, Sherrod PS. Warfarin embryopathy in siblings. Obstet
Gynecol 1981; 57: 673-6.
66. Howe AM, Webster WS. The warfarin embryopathy: a rat model showing
maxillonasal hypoplasia and other skeletal disturbances. Teratology
1992; 46: 379-90.
Table 1. The ten requirements for inclusion of pregnant women in
clinical trials outlined by the FDA [43]